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Abstract
Aims To evaluate the feasibility of a one-stop microvascular screening service for the early diagnosis of diabetic distal
symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at-risk diabetic foot.
Methods People with diabetes attending retinal screening in hospital and community settings had their feet examined
by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10-g monofilament test; and two
validated, objective and quick measures of neuropathy obtained using the point-of-care devices ‘DPN-Check’, a hand-
held device that measures sural nerve conduction velocity and amplitude, and ‘Sudoscan’, a device that measures
sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score
as the ‘gold standard’.
Results A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never
previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed
using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10-g monofilament test (14.4%).
The prevalence of distal symmetrical polyneuropathy using DPN-check was 51.5% (84.3% sensitivity, 68.3%
specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and
61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices
correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical
polyneuropathy was made in 59 participants (25%), and 56.6% had moderate- or high-risk foot. Participants rated the
service very highly.
Conclusions Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies
painful distal symmetrical polyneuropathy and the at-risk foot. Combined large- and small-nerve-fibre assessment using
non-invasive, quantitative and quick point-of-care devices may be an effective model for the early diagnosis of distal
symmetrical polyneuropathy.
Diabet. Med. 00: 1–8 (2018)
Introduction
The number of diabetes-related amputations in England has
now reached an all-time high of 20 per day [1], with the
annual number of diabetes-related amputations at 7370 [1].
Although there has been a very small but significant
reduction in major amputations per 10 000 people with
diabetes, this has been offset by the increase in both Type 2
diabetes and minor amputations [2]. Amputation is not only
devastating in its impact on the person with diabetes and
their family, leading to loss of independence and livelihood,
but also results in a remarkable consumption of scarce
medical resources and a very high mortality rate [3]. Yet, it is
estimated that 80% of amputations in England could be
prevented through improved healthcare and management of
diabetes [1].
Most amputations are preceded by foot ulceration, and
diabetic distal symmetrical polyneuropathy (DPN) is the
strongest initiating factor. DPN is very common, with a
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lifetime prevalence of 50% of all people with diabetes [4].
Currently, the clinical assessments we use to screen for
DPN, such as the 10-g monofilament test, identify those at
risk of foot ulceration but are not good for screening for
early neuropathy [5]. Unfortunately, these assessments
detect the disease very late, at a time when treatment is
unlikely to work. Furthermore, peripheral neurological
examination using bedside instruments, such as the tuning
fork and patella hammer, is not reproducible even when
performed by experts [6]. The situation is clearly different
for the detection of early retinopathy using digital retinal
photography and early nephropathy by measuring microal-
buminuria. The development of early disease markers and
the institution of robust screening programmes have had a
tremendous impact on disease outcomes. For example, the
institution of annual digital camera-based retinal screening
for all people with diabetes in the UK over the past decade
has contributed to significant reduction in blindness, such
that retinopathy is no longer the commonest cause of
blindness in working-age adults [7]. Currently, a robust
system of annual diabetes foot screening, as advocated by
Diabetes UK, is not fully in place in the UK [8]. Unfortu-
nately, by the time DPN is detected it is often very well
established and, consequently, it is impossible to reverse/halt
the neuropathic process. Many of these patients end up in
foot clinics and have very poor outcomes, with 5-year
mortality close to 50% [3].
To improve foot outcomes, there is an urgent need to
develop a high-uptake and effective diabetes foot screening
programme [8]. There has been a recent advance in the
development of non-invasive, objective, accurate point-of-
care devices (POCDs) that may be able to diagnose DPN
early, before overt clinical signs are apparent [9,10]. These
devices do not require specialist training to use in routine
clinical care and provide results within a few minutes.
The aims of the present study were to examine the
feasibity and patient acceptability of a combined eye, foot
and renal screening clinic and to evaluate the feasibility of
use and diagnostic utility of two POCDs in detecting DPN
early.
Methods
Study design and participants
Peripheral neurological examination
A total of 244 consecutive patients with either Type 1 or
Type 2 diabetes attending for annual eye screening in a
hospital (Northern General Hospital, Sheffield) and primary
care (Jordanthorpe Medical Centre, Sheffield) setting were
recruited between January 2015 and December 2016 into
this service development project, funded by Sheffield Teach-
ing Hospitals NHS Foundation Trust. Before undergoing
retinal photography and whilst the mydriatic was taking
effect, the feet were examined by a podiatrist (O.B.H.) in an
adjacent room for any abnormality, including deformity,
callus and ulceration. The presence of dorsalis pedis and
posterior tibial pulses were also assessed. Participants then
underwent Toronto Clincal Neuropathy Score (TCNS)
assessment [11] and the 10-g monofilament test (at five sites
in each foot, with an inability to feel ≥2 sites taken to
indicate DPN). The TCNS has been found to be a valid
instrument to reflect the presence and severity of DPN as
measured by sural nerve morphology and electrophysiology
[11], and was used in the present study as the ‘gold standard’
for the diagnosis of DPN against which all other measures of
DPN were compared. It takes ~15 min to perform the TCNS
assessment, which includes evaluation of symptoms (score 0–
6) and reflexes (0–8), and a sensory examination (0–10), with
a maximum score of 24, and a minimum score of 5 to
diagnose DPN. A score of 5–8 was regarded as mild DPN, 9–
11 as moderate DPN and ≥12 as severe DPN. Finally,
participants underwent assessment of large-fibre function
using ‘DPN-Check’ (Neurometrix Inc., Waltham, MA, USA)
[12] and small-fibre function using ‘Sudoscan’ (Impeto
Medical, Paris, France) [13] as described below. These
POCDs were chosen as they are both easily portable, provide
quick, objective quatitative results and have been validated
to detect DPN. As DPN involves both large and small fibres,
an objective assessment of both seemed reasonable.
Assessment of peripheral neuropathy using DPN-Check
Participants underwent sural sensory nerve conduction
velocity (SNCV; m/s) and amplitude [sural nerve action
potential (SNAP); lV] measurement in both the left and right
leg (to insure symmetry) using DPN-Check, and the average
was calculated [9]. These tests were conducted by the same
podiatrist, without any technical expertise in standard nerve
conduction study protocol, and with only 1-h training in the
use of this device. DPN-Check is a handheld POCD with
stimulating probes at one end and a disposable biosensor
What’s new?
• A novel, one-stop microvascular screening service in a
hospital and community setting was initiated, whereby
people with diabetes attending the annual eye screen-
ing, which has a high uptake, also underwent foot
assessment aimed at detecting early peripheral neu-
ropathy and the at-risk foot requiring referral to the
Foot Protection Team. Foot examination was carried
out by a podiatrist. The service also identified previ-
ously undiagnosed painful neuropathy and had a high
patient acceptability level.
• The service used novel, validated point-of-care devices
for combined large- and small-nerve-fibre assessment,
with the aim of diagnosing peripheral neuropathy early.
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9.22 cm at the other end. The biosensor covered a wide area
of the lateral aspect of the lower limb just above the ankle to
reliably record SNAP responses without the need for careful
positioning over the sural nerve by an expert electrophysi-
ologist. The device had a built-in infrared thermometer just
below the stimulating probes to measure skin temperature
near the ankle. Measured skin temperature was used to
normalize SNCV to an equivalent measured at 28°C. The
device had a screen that displayed SNCV and SNAP. Unlike
conventional electrophysiology equipment, DPN-Check
stimulated the sural nerve orthodromically. A single record-
ing took ~2 min. We used proprietary thresholds for the
diagnosis of DPN if either SNAP was >4 lV and/or SNCV
was < 40 m/s [12]. An abnormality in both legs was required
for a diagnosis of DPN [9,12].
Assessment of peripheral neuropathy using Sudoscan
Participants then underwent assessment of small-fibre neu-
ropathy using Sudoscan, a device developed to provide a
quick, non-invasive and reproducible [13], quantitative
assessment of sudomotor function [10]. This was performed
with participants placing their hands and bare feet on
electrode plates for 3 min [14]. Measurement was based on
an electrochemical reaction between electrodes and chloride
ions, after stimulation of small fibres innervating sweat
glands by a low-voltage current (<4 V) [10,13]. A measure-
ment of electrochemical skin conductance (ESC; lS) for the
hands and feet was generated from the derivative current
associated with the applied voltage [9]. Sudomotor dysfunc-
tion, and hence DPN, was diagnosed according to the ESC
measured on the feet with Sudoscan: foot ESC >60lS = no
DPN and <60lS = DPN. These threshold values were defined
on the basis of previous studies [14]. No special preparation
of participants was required.
Assessment of foot risk
In addition to neuropathy evaluation, the feet were also
carefully examined for deformity, callus, ulceration, ampu-
tations, gangrene, infection/inflammation, the presence of
foot pulses and Charcot arthropathy, and foot risk was
determined according to National Institute for Health and
Care Excellence (NICE) guidelines (NG19) [16].
Renal screening and questionnaires
Blood (urea and electrolytes, creatinine, estimated GFR) and
urine (albumin:creatinine ratio) tests for renal screening,
HbA1c, vitamin B12, liver function tests and lipid profile
were carried out if these had not been measured in the
previous 6 months. These results were readily available in
shared primary and secondary care records. The presence of
painful DPN was determined on the basis of the presence of
bilateral lower limb painful neuropathic symptoms (e.g.
paraethesia, burning, sharp shooting, deep aching, numbness
and contact hypersensitivity) for at least 3 months and a
TCNS > 5. Where this was the case, the average intensity of
neuropathic pain over the previous 24 h, with 0 indicating no
pain and 10 indicating worst pain imaginable (numeric
rating scale), was obtained. Finally a patient satisfaction
survey for this one-stop service (strongly against, against,
neutral, in favour, strongly in favour) was completed.
Statistical analysis
Statistical analysis was carried out using SPSS (version 21,
IBM). Group differences with regard to demographic char-
acteristics, and clinical and neurophysiological measures
were compared using Student’s t-tests/ANOVA for normally
distributed variables and the Mann–Whitney U-test for non-
normally distributed variables. For categorical variables the
chi-squared test for frequencies was used. Associations of
POCDs with DPN severity (TCNS score) were assessed using
Pearson’s coefficient correlation and linear regression. The
diagnostic validity of POCDs was analysed using receiver-
operating characteristic (ROC) curves to determine sensitiv-
ity, specificity and area under the curve (AUC). The optimal
thesholds for POCDs to distinguish between the presence or
absence of DPN was determined by calculating the Youden’s
index. Using the optimized POCDs thresholds, ROC curves
were generated to compare the POCD results [results from
each POCD and combined POCD results (either Sudoscan or
DPN-Check results below threshold)] with DPN status, as
defined by TCNS. The TCNS threshold used for this analysis
was the presence of DPN regardless of severity, i.e. a TCNS
score >5. We used a second approach to develop an
algorithm for the use of POCDs in a clinical context. Two
threshold values were determined, one that maximized
sensitivity and the other that maximized specificity, such
that the negative likelihood ratio would approach 0.1, while
the positive likelihood ratio would approach 10. A sample
size of at least 106 (53 DPN cases) had > 97.5% probability
to discriminate a conservatively modelled AUC 0.80 from the
null hypothesis in which the diagnostic accuracy was no
different from chance alone (AUC 0.5) [17]. An a-level of
0.05 was used for tests of statistical significance. Normality
distribution of study measures was assessed graphically and
using the Kolmogorov–Smirnov test.
Results
Altogether, data from 236 participants were analysed [mean
age (SD) 63.5(14.1) years; 61.4% men; 97.8% with Type 2
diabetes (Table 1)]. Eight participants [mean (SD) age 72
(11.2) years] were excluded because of missing data for one
or both POCDs: seven were missing DPN-Check results
(three were non-compliant, two had severe lower-limb
oedema and two underwent amputations) and five were
missing Sudoscan results (technical issues and amputations).
A total of 33 participants (14.1%) had previous foot ulcers
and four (2.1%) had undergone previous amputations. Just
under half of the participants (43%) recalled being provided
ª 2018 The Authors.
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with basic foot care education [18]. Only 46 participants
(18.9%) had documented evidence of foot screening com-
pleted in the previous 12 months, five of whom (10.9%) had
a history of foot ulceration. Foot risk assessment showed that
43.4% had a low, 38.5% a moderate and 18.1% a high risk
of foot ulceration [16].
Using the TCNS as the gold standard for the diagnosis of
DPN, we divided the participants into those with no DPN
(n=163, 69.1%) and those with DPN [mild DPN, n=34
(14.4%); moderate DPN, n=19 (8.1%) and severe DPN n=20
(8.5%)]. Participants with DPN were older (P=0.01;
Table 1) and were more likely to have had a previous foot
ulcer (chi-squared test 36.4, P<0.001) and/or amputation
(chi-squared test 24.2, P<0.001). There were no differences
in HbA1c (P=0.75) or urine albumin:creatinine ratio (ANOVA,
P=0.07). Participants with DPN had significantly lower
SNCV (P<0.001) and SNAP (P<0.001) and Sudoscan hand
(P<0.001) and foot (P<0.001) ESC (Table 1). The prevalence
of DPN based on TCNS (>5) was 30.9%. A positive 10-g
monofilament test was present in only 34 participants
(14.4%). The mean (SD) TCNS was significantly higher in
participants who had a positive 10-g monofilament test vs
those with a negative test [8.35 (4.6) vs 4.18 (3.7); P<0.001].
The prevalence rates of DPN based on DPN-Check
(abnormal SNCV and/or SNAP) and Sudoscan foot ESC
were 51.5% and 38.2%, respectively.
When choosing a Sudoscan foot ESC threshold of ≤58.5 lS
(optimal Youden index), sensitivity was 77.4%, specificity
was 68.3% and the Youden index was 0.45 (Fig. 1). The
area under the ROC curve was 0.75. The diagnostic
performance of hand ESC (Youden index 0.30, sensitivity
73.6%) was poorer in comparison with foot ESC. DPN-
Check SNAP (threshold ≤ 4.3 lV, Youden index 0.53) and
SNCV (≤ 46.3 m/s, 0.52) had sensitivity (84.3%, 72.3%) and
specificity (68.3%, 80.0%), respectively. The area under the
ROC curve was 0.84 and 0.81 for SNAP and SNCV,
respectively (Fig. 1). The 10-g monofilament test sensitivity,
specificity and AUC were 30.0%, 92.7% and 0.61, respec-
tively.
Next, we examined the efficiency of combined Sudoscan
and DPN-Check assessments using the proprietary thresholds
for normality. The sensitivity of combined assessments
improved to 93.2%, but specificity fell to 52.8% (Youden
index 0.46, AUC 0.73). Both Sudoscan and DPN-Check
results were significantly correlated with TCNS score
(P<0.001; Table 2). To further explore the relationship of
POCDs, age and DPN, we examined POCDs values (e.g.
DPN-Check SNCV or SNAP) across a range of DPN
Table 1 Clinical characteristics and demographics of the study population
Total study population
Number of participants 236
Mean (SD) age, years 63.5(14.1)
Gender: male, n (%) 145(61.4)
Type 2 diabetes, n (%) 231(97.8)
No DPN Mild DPN Moderate DPN Severe DPN
Number of participants, n (%) 163 (69.1) 34 (14.4) 19 (8.1) 20 (8.5)
Mean (SD) age, years* 61.6 (14.3) 66.8 (12.9) 66.1 (13.9) 67.9 (12.7)
Type 2 diabetes, n (%) 154 (95.1) 33 (100) 18 (94.7) 19 (95.0)
Previous ulcer†, n (%) 11 (6.7) 7 (20.0) 4 (21.1) 11 (55.0)
Amputation†, n (%) 0 1 (2.9) 0 3 (15.0)
Mean (SD) HbA1c
mmol/mol 60.7 (18.8) 61.3 (19.8) 58.4 (22.1) 68.1 (23.2)
% 7.7 (3.9) 7.8 (4) 7.5 (4.2) 8.4 (4.3)
Mean (SD) albumin:creatinine ratio 6.5 (21.4) 22.7 (54.4) 2.4 (2.1) 8.5 (14.9)
Systolic blood pressure, mmHg 139.3 139.4 137.3 135.1
Diastolic blood pressure, mmHg 80.1 82.0 77.7 82.3
Positive 10-g monofilament test, n (%) 12 (7.4) 4 (11.8) 11 (57.9) 7 (35.0)
DPN-Check
Mean (SD) right sural SNAP‡, lV 10.2 (6.3) 5.4 (3.2) 4.8 (5.5) 2.2 (1.1)
Mean (SD) right sural SNCV‡, m/s 51.3 (11.9) 39.2 (12.4) 33.6 (14.8) 27.6 (15.5)
Mean (SD) left sural SNAP‡, lV) 10.2 (6.0) 5.3 (3.4) 4.3 (5.3) 1.8 (0.98)
Mean (SD) left sural SNCV‡, m/s 49.7 (11.3) 43.0 (10.7) 34.3 (17.3) 23.9 (10.3)
Sudoscan
Mean (SD) hand ESC‡, lS 66.7 (13.3) 63.0 (12.5) 51.7 (17.9) 52.3 (18.8)
Mean (SD) foot ESC‡, lS 65.2 (14.5) 53.5 (16.6) 49.5 (14.4) 48.4 (21.7)
DPN, diabetic distal symmetrical polyneuropathy; ESC, electrochemical skin conductance; SNAP, sural nerve action potential; SNCV, sural
nerve conduction velocity.
*t-test comparison between no DPN and any DPN (mild, moderate and severe as one group) P<0.01; †chi-squared test P<0.001; ‡Mann–
Whitney U-test P<0.001.
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severities [mild, moderate and severe; Fig. 2 (DPN-Check
SNCV) and Fig. 3 (DPN-Check SNAP), respectively], subcat-
egorized into different age ranges (20–49, 50–59, 60–69 and
70–99 years). All POCD results had a significant, stepwise,
inverse linear relationship with ordinal categories of increas-
ing DPN severity (linear regression: DPN-Check SNAP b=–
0.43, P<0.001; DPN-Check SNCV b=–0.56, P<0.001; Sudos-
can foot b=–0.36; P<0.001). There was also stepwise reduc-
tion in each POCD result with each DPN category.
Finally, to develop an algorithm for using POCDs within a
clinical context, we sought two additional thresholds for
each POCD, one that maximized sensitivity and one that
maximized specificity (Fig. 4). For DPN-Check the SNAP
and SNCV values used to rule in DPN were <3.75 lV
(negative likelihood ratio 0.11) and <24.3 m/s (negative
likelihood ratio 0.1), respectively. For Sudoscan, the foot
ESC used to rule in DPN was 46.5 lS (negative likelihood
ratio 0.20). To exclude DPN we used a SNAP value of
>16.75 lV (positive likelihood ratio 10.32), an SNCV value
of >59.7 m/s (positive likelihood ratio 10.32) and a Sudoscan
foot ESC value of >79.5 lS (positive likelihood ratio 4.33).
The following clinical algorithm for using POCDs was
proposed: (1) no DPN – SNAP >16.75 lV or SNCV > 59.7
m/s or Sudoscan foot > 79.5 lS (sensitivity 94.6% and
negative predictive value 97.1%) and (2) DPN – SNAP <3.75
lV or SNCV <24.3 m/s or Sudoscan foot < 46.5 lS
(specificity 82.2% and positive predictive value 70.1%).
Using this diagnostic algorithm, 153 of 236 participants
(64.8%) were classified as having DPN (n=84) or no DPN
(n=69) by the POCDs, while 83 participants (35.2%) were
left unclassified.
A total of 59 participants (25%) were diagnosed with
painful DPN with a mean 24-h pain score of 5.3 (2.8).
Overall, 215 participants (91.1%) reported they were either
‘in favour’ (18.6%) or ‘strongly in favour’ (72.6%) of a ‘one-
stop’ microvascular screening service, with 8.9% being
‘neutral’ and no one ‘against’ this service. No adverse events
or discomfort during and after measurements were reported.
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FIGURE 1 Receiver-operating characteristic curve for the identification
of diabetic distal symmetrical polyneuropathy (DPN) using point-of-
care devices DPN-Check and Sudoscan. ESC, electrochemical skin
conductance; MF, monofilament; SNAP, sural nerve action potential
amplitude; SNCV, sural nerve conduction velocity. Symbols ◊, *, ǂ and
¥ represent thresholds for DPN-Check SNCV, SNAP, Sudoscan foot
and hand ESC, respectively.
Table 2 Spearman correlations (r) between Toronto Clinical
Neuropathy Score and point of care device results
Sudoscan
feet ESC (lS)
DPN-Check
SNAP (lV)
DPN-Check
SNCV (m/s)
TCNS 0.43* 0.70* 0.70*
ESC, electrochemical skin conductance; SNAP, sural nerve
action potential amplitude; SNCV, sural nerve conduction
velocity; TCNS, Toronto Clinical Neuropathy Score
*P<0.001.
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FIGURE 2 Box and whisker plots of point-of-care device DPN-Check
mean of left and right sural sensory nerve conduction velocity (SNCV)
for each neuropathy group, subdivided into to age ranges. 6¼ ANOVA
P<0.05.
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FIGURE 3 Box and whisker plots of point-of-care device DPN-Check
mean of left and right sural sensory nerve amplitude (SNAP) for each
neuropathy group, subdivided into to age ranges. 6¼ ANOVA P<0.05.
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Discussion
The Toronto Consensus meeting [19] defined DPN as a
symmetrical and length-dependent sensorimotor polyneu-
ropathy that may involve motor, sensory and autonomic
nerves as a result of chronic hyperglycaemia and vascular
risk factors [20]. It is now well recognized that DPN and its
sequelae have major impacts on quality of life, morbidity and
mortality and confer considerable healthcare costs [3].
Unfortunately, DPN has an insidious onset and the majority
of people with DPN will have no symptoms. For this reason,
the recent American Diabetes Association (ADA) position
statement on diabetic neuropathy recommends annual
assessment for DPN using simple bedside instruments,
starting at diagnosis of Type 2 diabetes and 5 years after
diagnosis of Type 1 diabetes [21]. The NICE guidance on
prevention and management of diabetic foot problems makes
a similar recommendation (NG19) [16]. The present study
and a recent report [8], however, have shown that this
recommendation is not currently being adhered to. There
may be many reasons for this. First, the diabetes consultation
is currently centred on glucose control, the management of
hypertension and elevated cholesterol level, and the careful
examination of the feet with shoes and socks taken off may
not be considered a priority. Even when foot risk has been
assessed, the management of diabetic foot disease, as advised
by NICE, may not be undertaken appropriately [8]. Second,
in the UK primary care setting, foot screening may not
always be undertaken by healthcare professionals who have
the necessary clinical skills. Third, the ADA recommendation
of assessing either temperature or pinprick sensation (small-
fibre function) and vibration sensation using a 128-Hz tuning
fork (large-fibre function) in addition to the use of the 10-g
monofilament, which is a good way of diagnosing foot ulcer
risk, is not routinely undertaken [21]. This contrasts with
screening for retinopathy and renal disease, for which there
are clearly established screening methods aimed at detecting
the complications early and integrated management path-
ways, and, in the case of retinopathy, the screening has a very
high uptake.
Given the rising tide of amputations in the UK [2,3],
there may be a good rationale for a robust, high-uptake
DPN screening service, aimed at diagnosing the disease
early at a point when it can be halted, in both Type 1 (level
A evidence) and Type 2 diabetes (level B evidence) [21], and
insuring the implementation of the NICE guideline NG19
for the ‘at-risk diabetic foot’ [21]. The results of the present
study show that combined eye, foot and renal screening in a
one-stop microvascular screening clinic [22] was feasible
and had high patient acceptability and uptake (91.1% of
patients in favour of this service). Moreover, this service
was conducted by a podiatrist with the skills to assess foot
risk and footwear and to refer at-risk patients appropri-
ately.
Study populaon n=236
Point of Care Device
No DPN
n=69
DPN
n=84
Unclassiﬁed
n=83
SNAP >16.75 μV or SNCV > 
59.7m/s or SUDOSCAN 
foot ESC > 79.5μS
SNAP <3.75μV or SNCV 
<24.3m/s or Sudoscan 
foot ESC < 46.5μS
Sensivity=94.6%
NPV=97.1% 
Speciﬁcity=82.2%
PPV=70.1% 
Screen every 
2 years
10g MF Annual 
screening
Posive: refer 
to Foot 
Protecon 
Team
Negave: 
Intensive risk 
factor 
intervenon 
FIGURE 4 Proposed diagnostic algorithm for the clinical application of the point-of-care device (DPN-Check or Sudoscan). DPN, diabetic peripheral
neuropathy; ESC, electrochemical skin conductance; MF, monofilament; NPV, negative predictive value; PPV, positive predictive value; SNAP, sural
nerve action potential; SNCV, sural nerve conduction velocity.
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Current bedside assessments for DPN, such as the 10-g
monofilament test, are primarily aimed at screening for
those at risk of foot ulceration and can be used to diagnose
DPN when it is well established [21], but late diagnosis
hampers the benefits of early identification, the focus on
early, intensified diabetes control, and the prevention of
neuropathy-related sequelae [21]. The Toronto Consensus
Panel recommended that to confirm a diagnosis of DPN,
abnormal nerve conduction studies and/or a validated
measure of small-fibre neuropathy (with level A evidence)
are required [19]; however, measurement of a complete set
of electrophysiological variables requires an expert neuro-
physiologist and is time-consuming and expensive, and
access to care is hindered by the limited number of clinics
available to perform standard nerve conduction studies in
the face of the increasing prevalence of diabetes. A novel
point-of-care nerve conduction device, DPN-Check, has
been developed that has the potential to serve as an
acceptable proxy to standard nerve conduction studies
[9,23] for screening and identification of DPN in clinical
practice and can be performed within 5 min [24]. Recent
studies have also shown early small-fibre involvement in
DPN [25]. Sudomotor dysfunction, a measure of small-fibre
neuropathy, is one of the earliest detectable abnormalities in
DPN [26]. Sweat glands are innervated by sudomotor,
postganglionic, thin unmyelinated cholinergic sympathetic
C-fibres, and a number of skin biopsy studies have shown a
reduction in the epidermal C-nerve fibres in people with
diabetes [27]; therefore, a rapid assessment of sudomotor
function may provide an attractive tool to evaluate periph-
eral small-fibre neuropathy in diabetes [25]. Indeed as DPN
involves both small and large fibres early in its course [28],
there is a good rationale for combining DPN-Check and
Sudoscan to screen for DPN.
The present study showed that both POCDs were patient-
friendly, and easy and quick to use in a hospital- and
community-based, one-stop microvascular screening service.
With combined assessment using DPN-Check and Sudoscan,
an abnormality in the results of one or both indicating DPN
correctly classified 73% of patients with 93.2% sensitivity.
Moreover there was good correlation between POCD results
and TCNS, indicating diagnostic utility across the range of
DPN severity. We propose the following clinical algorithm to
enable easy adoption with the potential to personalize
treatment pathways. All patients with abnormal POCDs
confirming DPN could be offered intensive, target-driven risk
factor reduction including glucose control, optimization of
vascular risk factors and lifestyle modification [21]. In
addition, those with loss of protective foot sensation (positive
10-g monofilament) could also be referred to the Foot
Protection Team (podiatry and orthotics) for further assess-
ment and treatment. We would also suggest that, whilst
people who are unclassified by this algorithm will require
annual screening, those who have no evidence of DPN may
require screening every 2 years. Finally, compared with
standardized clinical examination, which is less reproducible
whilst being more time-consuming, requires additional
training and patient cooperation, there may be a good
rationale for using POCDs.
Early identification of participants with insipient neuropa-
thy using these validated, yet novel non-invasive methods
will allow targeted intensified metabolic control and other
potential new treatment interventions in order to prevent
clinical DPN or halt disease progression [21]. Ultimately, the
prevention of DPN may have the greatest impact on reducing
amputations dramatically because >80% of patients attend-
ing the diabetic foot clinic with foot ulcers [29] and virtually
all diabetes amputees have DPN. Clearly, in those with
established DPN, careful foot ulcer risk assessment (includ-
ing peripheral vascular status, deformity, callus etc.) and
appropriate management (provision of foot information and
contacts, footwear, podiatry etc.) are warranted [16]. A one-
stop microvascular screening service will employ a specialist
podiatrist to perform this task, assess level of risk and
manage patients appropriately in order to prevent foot
ulceration and amputation. The widespread implementation
of retinal screening in the UK has had a dramatic impact on
reducing working-age blindness, and a similar robust
approach to initiating high-uptake foot screening may prove
to be a game-changer.
Several critical lines of future research emerge from the
present study including: further large, longitudinal studies
looking at hard outcomes such as the development of clinical
DPN; hospital admissions with foot-related problems; inci-
dent foot ulceration and amputations; quality of life; and the
cost-effectiveness of such an approach.
The study also led to significant detection of undiagnosed
painful DPN (25%). Many of these patients reported
moderate to severe painful symptoms and were referred to
the painful neuropathy clinic for treatment. People with
painful DPN often do not make the connection between their
lower limb neuropathic symptoms and diabetes. This results
in underdiagnosis, and hence undertreatment and consider-
able suffering [30]. The one-stop service described in the
present study provides a valuable oppportunity to identify
such patients and intervene appropriately.
In conclusion, a one-stop microvascular assessment,
recently highlighted by Vas and Edmonds [22], is feasible,
has a high uptake and reduces clinic visits and identifies
painful DPN. The study has also shown that the use of the
POCDs DPN-Check and Sudoscan, which provide objective
and quantitative measures of DPN, was feasible within this
one-stop service. An abnormality in the results of either
(abnormal SNCV and/ or SNAP and/or Sudoscan foot ESC)
had a sensitivity of 93.2% for detecting DPN defined by
TCNS, and there was a strong correlation of PCOD results
with the TCNS. Widespread implementation of a one-stop
microvascular screening service may therefore be an effective
model for the early diagnosis of DPN and foot complica-
tions.
ª 2018 The Authors.
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